Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer

American Journal of Health-System Pharmacy

Volumn 70, Issue 18, 2013, Pages 1579-1587

  Chung, Clement ^a,b   Lam, Masha S H ^c  

^a Lyndon B Johnson General Hospital   (United States)

^b Kennewick General Hospital   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPITOPE; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ALOPECIA; ASTHENIA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; DIARRHEA; DISEASE FREE INTERVAL; DRUG BINDING; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRY SKIN; ELIMINATION HALF-LIFE; FEBRILE NEUTROPENIA; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2 POSITIVE BREAST CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; VOLUME OF DISTRIBUTION; BREAST NEOPLASMS; ECONOMICS; FEMALE; GENETICS; METASTASIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COSTS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 84894587631     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120735     Document Type: Review

References (37)

1. National Cancer Institute. SEER stat facts sheets: breast cancer. http://seer.cancer.gov/statfacts/html/breast.html (accessed 2012 Nov 20).
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177-82.
3. Yamauchi H, Woodward WA, Valero V et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17:891-9.
4. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-92.
5. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment; the M77001 Study Group. J Clin Oncol. 2005; 23:4265-74.
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354:809-20.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-72.
8. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100(suppl 1):abstract 2.
9. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor 2-positive operable breast cancer. J Clin Oncol. 2005; 23:3676-85.
10. Petrelli F, Borgonovo K, Cabiddu M et al. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs. 2011; 22:128.
11. Hutka M, Okines AF, Cunningham D. Trastuzumab in gastric cancer. Int J Clin Rev. 2011; 7:4.
12. Tzahar E, Waterman H, Chen X et al. A hierarchical network of interceptor interactions determines signal transduction and epidermal growth factor. Mol Cell Biol. 1996; 16:5276-87.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nature Rev Mol Cell Biol. 2001; 2:127-37.
14. Pinkas-Kramarski R, Soussan L, Waterman H et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996; 15:2452-67.
15. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast cancer. J Clin Oncol. 1999; 17:2639-48.
16. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20:719-26.
17. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling. Cancer Cell. 2004; 5:317-28.
18. Cortés J, Fumoleau P, Bianchi GV et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012; 30:1594-1600.
19. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6:443-6.
20. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2:127-37.
21. Adams CW, Allison DE, Flagella K et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006; 55:717-27.
22. Ng CM, Lum BL, Gimenez V et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006; 23:1275-84.
23. Agus DB, Gordon MS, Taylor C et al. Phase I study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005; 23:2534-43.
24. Yamamoto N, Yamada Y, Fujiwara Y et al. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009; 39:260-6.
25. Attard G, Kitzen J, Blagden SP et al. A Phase Ib study of pertuzumab, a recombinant humanized antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer. 2007; 97:1338-43.
26. Cortes J, Baselga J, Kellokumpu-Lehtinen P et al. Open-label, randomized phase II study of pertuzumab in patients with metastatic breast cancer with low expression of HER2. Presented at 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; 2005 May 13-17. Abstract 3068.
27. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28:1138-44.
28. Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res. 2008; 14:2710-6.
29. Lu D, Burris HA, Wang B et al. Drug interaction potential of trastuzumab emtansine (T-DMI) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab. 2012; 13:911-22.
30. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13:25-32.
31. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366:109-19.
32. Perjeta (pertuzumab) product information. South San Francisco, CA: Genentech, Inc.; 2012.
33. Lenihan D, Suter T, Brammer M et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 2012; 23:791-800.
34. Red book online [Internet database]. Pertuzumab (Perjeta). www.micromedex solutions.com (accessed 2012 Nov 30).
35. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer, version 3 (2012). www.nccn.org (accessed 2012 Nov 12).
36. ClinicalTrials.gov. A study of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with HER2-positive metastatic breast cancer (PHEREXA). http://clinicaltrials.gov/show/NCT01026142 (accessed 2013 Feb 12).
37. ClinicalTrials.gov. A study of pertuzumab in addition to chemotherapy and Herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast cancer. http://clinicaltrials.gov/show/NCT01358877 (accessed 2013 Feb 12).